The Use of Oral, Topical and Intravenous

Detoxification Strategies in the Management of

Cancer and Other Diseases

Victor A Marcial-Vega,MDwww.marcialvegamd.commarcialvegamd@aol.com

April 2013

Patient Population

210 Patients in Puerto Rico Age Range 10-88 years old 98% Treated between 2/08-

9/10 Treated in our clinic since 7-1-

10 Before 7-1-10 treated at home 27 excluded from results

analysis

Baseline Studies

CBC CMP-20 Lipid Profile Salivary pH (Alkaline versus Acid) High Resolution Blood Imaging CT Scans, PET scans, etc. Heavy Metals

Heavy Metals

21 patients tested 100% presence of metals Lead, mercury, aluminum Cadmium, gadolinium, platinum,

tin, nickel Uranium, cesium

Goals of Treatment

To promote well being in our patients

Remove toxinsRegenerate tissue

TREATMENT

Goji Chlorella Lactobacillus Vitamin C Meditation CD Essential Oils

Meditation CD

50 patients Listening daily for 2 weeks Decrease pain medications in 50%

pts Decrease HBP meds in 20% More calm and focused More aware of what is causing

their discomfort

Essential Oils

Pain, Peppermint, Circulation Birch, Marjoram, Sages, Lavender 150 patients 90% reduction or dissapearance of

pain Effects noted in 5 minutes No side effects

Essential Oils for Relaxation

Stress Blend Meditation Blend Anxiety Fem Balance Geranium Rose, Y lang, Juniper

Berry, Orange Peel, Patchouli, Vetiver, Chamomille blue,

IV Therapies

Vitamin C above 5 grams 83% EDTA 50% Na2CO3 35% H202 6% Glutathione 17%

Vitamin C Treatments

1036Average Number of Treatments

Per patient 12

IV Vitamin C Indications

Feeling Better More Energy Cancer (on chemo or radiation) Before Surgery As a treatment for Cancer or any

other disease 3x-5x week

EDTA Indications

Any DiseaseCardiovascular Plaque Formation

Once a week

Bicarbonate Indications

Salivary pH less than 7.0Now, we see that aggressive IV Vitamin C can alkalinize most patients

Glutathione Indications

Parkinson’s disease, patients on any chemotherapy (risk of neuropathy)

Nerve or brain damage

Hydrogen Peroxide

Presence of InfectionOr risk of an infection after a procedure

EDTA Treatments

6656 per patient

Na2Co3 Treatments

365Average Treatments/pt = 5

Glutathione

Total Number 94Average Per patient 3

H202

Total 38Average/pt 3

RESULTSFLU AND RESPIRATORY

22 patients with influenza, bronchiectasia, asthma or chronic bronchitis

One treatment of either Vitamin C, Bicarbonate or hydrogen peroxide clears 50% of symptoms during the infusion

One pt increased flow from 44 to 88%

FLU AND RESPIRATORY

Overall response was 21/22 during the IV (95%)

17 patients rapidly improved within 6 hours after the IV

Vit C 20-50 g Hydrogen Peroxide 3cc Sodium Bicarbonate 150-200 cc

ARTHRITIS

9 patients Marked improvement or

disappearance of pain in 8/9 patients

One patient got worse from treatment and she was on methotrexate and prednisone

CHOLESTEROL

19/21 had a marked improvement Decrease in Cholesterol (84%) Decrease or elimination of meds

(81%) Decreased obstruction of vessels Lowering of Blood Pressure (85%)

DIABETES

12 patients Improved sugar levels in all

patients Improved quality of life Stopped medication-2

GENERAL

46 patientsSleeping better and more energy

Cancer Palliation

6 patients Improvement of Symptoms in 3

(50%) Enhanced quality of life and death process

Treatment of Side Effects from chemotherapy and

Radiation 13 patients 100% Resolution of Symptoms Nausea, vomiting, joint pains,

diarrhea, insomnia, low energy, bronchtis, allergies, asthma, leg swelling

RESULTS AS SOLE TREATMENT

Cancer Patients 60 Treatment Alone Most were Stage 4 43/60= 72% Response Rate

RESPONSE

Reduction of Tumor 27/60=45% Increased Energy and Wellbeing Increased Quality of Life Improvement of Symptoms 4 had a complete response 7% 2 additional CR unbiopsed

(6/60=10%) Heavily Treated Patients (chemo,

rt)

Case Histories

Metastatic Ovarian Carcinoma 51 years old CA-125 down from 26 to 12

then up to 65 , Alkaline Phosphatase down, decreased urine protein down 10 x 44.5g, 3 x 150, 3 x .7, 3 x 1.8 Glut. Patient Stable for 1 year

Hypernephroma

71 years old Decreased Kidney Nephroma Tumor from 12 x 13 to 5 x 7

cm. Improved KS 31 x 32g 6 x 158 cc 23 x 3g

DIED from chemotherapy complications

Metastatic Breast Cancer

58 years old 2 x .7 10 x 40g 4 x 156 cc Drop in Alkaline Phosphatase Drop in Liver Function Studies Complete Resolution of Severe

Pain

Prostate Cancer

Progression of PSA elevation 8 x 2.44, 17 x 61 g Decrease of PSA after stress

reduction modalities

Multiple Myeloma

20(2.1 grams), 20(64 grams)

Decline in IgG, mspike, gamma globulin, urine m-spike)

 

Breast Cancer Nodal Recurrence

Reduction from 4x4 to 3 x 3.5 2(20), 23(159)

Metastatic Carcinoid

19(40), 1-150 Disappearance of cough and 2

lung infiltrates 5 Hydroxy Indol Acetic Acid 12.1 to 7.0 to 3.4 4-8-10,

Down to 2.4 9-8-10

Recurrent Prostate Cancer

39(2.6g), 46(45g), 2(150cc), 3(1.9g)

PSA from 26 to .38 One year no evidence of

disease

Metastatic renal cell carcinoma

R DJD node gone 4 x 4 fixed Died of uncontrolled disease 4(15), 2(125) Stopped Treatment

Metastatic Pancreatic CA

7(31), 2(200) Peaceful Death Walking until the day he

died

Recurrent AM Leukemia

Hb up from 7.2 to 8.6 in 3 weeks, 12(48)

More energy and stamina Another patient had increase

in Hb from 9 to 12.5

Stage 4 Ulcerated Breast CA

Tumor reduced in size from 14.5x10(16 circumference) to 7x11(12 circumference)

60% by volume 14(62), 4(200)

Adnexal Mass(Fallopian Tube)

Severe pain, bleeding, 8.5 x 4 cm by Sonogram and CT

Reduced by ½ in one week Bleeding stopped no pain or

fevers. 3(35), 2(200),1(3) Operated 9-16-10

Concomitant RT and/or Chemo

27 -Reduced Side Effects 14 complete responders = 52% 10 More than 50% reduction of

tumor Overall Response Rate=

24/27=89% 3 patients that responded were

prohibited by oncologist to stop vitamin C. All are dead

Case Histories

7 years old Recurrent Neuroblastoma Disappearance of Tumor Markers Third chemotherapy program

Metastatic Colon Carcinoma

67 years old 5(.6), 20(51.5) and Cisplatin CEA down from 133.51 to

85.66, then to 55.06 8-12, Then 8-30-10 25.22 BIGGEST DROP associated with EDTA calcium 3x week, 2(40/.9)

Metastatic Breast Cancer

36 years old 16(45) On Mab More energy and sleeping

better. Excellent response (blindness reversed)

Rash Gone

Metastatic Ovarian cancer

6(29), 1(150), CA125 2-9-9 169 10 9-21-09 and has stayed

there until 9-10 2(35/.5), PET SCAN decreased

to ½. Feeling great

Sickle Cell Anemia

28 years old Ferritin 2319, steadily rising for 1.5

years,went down to 1670 after 5 EDTA's (1.9) given over 2.5 months 3-9 to 5-22-09, 10(1.9), 10(150)

 

Chronic Renal Failure

Creat 9.9, Heavy Metals, Hyperglycemia, TCC Bladder

2(100mg) CALCIUM EDTA, 3(5 grams Vit C) Less edema, less swelling of eyelids and legs. No more pains Sleeping better

diabetic, sjogrens,renal failure, improved skin and decreased creatinine from 3.5 to 2.78, 9(.180), 3(7.7)

COMPLICATIONS

2198 infusions 38/2198=2% Serious =.2% Of patients, 2% serious Hipoglycemia 9 patients Clot from axilla to fingers Lower in a clinic setting

COMPLICATIONS

Death associated to Toprol induced bradychardia.

Minor Side Effects-General malaise, fatigue, worsening of pain, thirst, stomach upset, dysuria, increased blood pressure, nosebleed, infiltration

Results seem much better and faster in a clinic than in a home setting

CONCLUSIONS

Intravenous Therapies are highly effective in the management of the flu, diabetes, vascular disease, arthritis and cancer

High dose intravenous vitamin C seems to increase the response rate of conventional chemotherapy

CONCLUSIONS

Intravenous Vitamin C markedly reduces side effects associated with conventional cancer treatment

Intravenous Vitamin C, EDTA and Bicarbonate can reduce tumors and markedly increase quality of life in cancer patients

CONCLUSIONS

EDTA/VITAMIN C intravenously is associated with a better response to treatment

All diseases are associated with heavy metals and their removal seems to lead to reversal of disease

Being told by oncologist to stop IV therapies is a negative prognostic factor